Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-
dose regimen, may be an option for the extended treatment of venous thromboembolism …

Background Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify
the treatment of venous thromboembolism. Methods In this randomized, double-blind study …

Background Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being
increasingly used in routine clinical practice because of their fixed dosing and favourable …

A model‐based approach was used to integrate data from a phase II study in order to
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …

Background: Apixaban, an oral potent reversible direct inhibitor of activated factor X, has
shown promise in the prevention of venous thromboembolism following major orthopedic …

Background: Anticoagulation is recommended as standard of care for venous
thromboembolism (VTE)(pulmonary embolism [PE]/deep vein thrombosis [DVT]), for which …

Background: Apixaban and rivaroxaban are replacing vitamin K antagonists for the
treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons …

Background Although many patients with venous thromboembolism require extended
treatment, it is uncertain whether it is better to use full-or lower-intensity anticoagulation …

For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …

Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …